The effect of Guanxin Shutong Capsules in the treatment of patients with acute myocardial infarction with percutaneous coronary intervention and its effects on oxidative stress and platelet activation
JIN Dapeng ZHANG Aiwen DING Zhenjiang▲ WANG Wenfeng LYU Dan
Department of Cardiology, Affiliated Hospital of Chengde Medical Univercity, Hebei Province, Chengde 067000, China
Abstract：Objective To study the effect of Guanxin Shutong Capsules in the treatment of patients with acute myocardial infarction (AMI) with percutaneous coronary intervention and its effects on oxidative stress and platelet activation. Methods The 80 elderly patients with AMI undergoing percutaneous coronary intervention in Affiliated Hospital of Chengde Medical Univercity from February 2016 to September 2017 were devided into control group (routine treatment) and observation group (Guanxin Shutong Capsules) according to the random number table method, with 40 patients in each group. The clinical efficacy , the levels of superoxide dismutase (SOD), malondialdehyde (MDA) and nitric oxide (NO), and the contents of platelet activation index such as lysosomal membrane glycoprotein (CD63), platelet alpha granule membrane glycoprotein (CD62p) and monocyte platelet aggregates (MPA) preoperative and postoperative in two groups were compared. Results The total effective rate in the observation group was higher than that of the control group, the difference was statistically significant (P ＜ 0.05). After operation, the levels of SOD and NO in the observation group were higher than that of the control group, the level of MDA was lower than the control group, the differences were statistically significant (P ＜ 0.05). After operation, the contents of CD63, CD62p, MAP were lower than before operation in two groups, and the observation group was lower than the control group, the differences were statistically significant (P ＜ 0.05). Conclusion Guanxin Shutong Capsules can significantly improve the clinical efficacy for elderly patients with AMI undergoing percutaneous coronary intervention, inhibit the oxidative stress and platelet activation, and play the myocardial protection role.
金大鹏 张爱文 丁振江▲ 王文丰 吕丹. 冠心舒通胶囊对老年急性心肌梗死经皮冠状动脉介入治疗患者的效果及对其氧化应激、血小板活化功能的影响[J]. 中国医药导报, 2018, 15(11): 59-62.
JIN Dapeng ZHANG Aiwen DING Zhenjiang▲ WANG Wenfeng LYU Dan. The effect of Guanxin Shutong Capsules in the treatment of patients with acute myocardial infarction with percutaneous coronary intervention and its effects on oxidative stress and platelet activation. 中国医药导报, 2018, 15(11): 59-62.
[1] Hou LL，Gao C，Feng J，et al. Prognostic factors for in-hospital and long-term survival in patients with acute ST-segment elevation myocardial infartction after percutaneous coronary intervention [J]. Tohoku J Exp Med，2017， 242（1）：27-35.
[2] Velders MA，Abtan J，Angiolillo DJ，et al. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention [J]. Heart，2016，102（8）：617-625.
[3] Dio M，Nosaka K，Miyoshi T，et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction：a randomized，controlled study [J]. Int J Cardiol，2014，176（3）：577-582.
[4] Lavall MC，Bonfanti G，Ceolin RB，et al. Oxidative profile of patients with ST segment elevation myocardial infarction [J]. Ann Noninvas Electro，2016，62（5）：971-973.
[5] Farukturk I，Arifyalcin A，Biyik I，et al. Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction [J]. Minerva Cardioangiol，2014，62（5）：389-397.
[6] Lee WC，Chen HC，Fang HY，et al. Comparison of different strategies for acute ST-segment elevation myocardial infarction with high thrombus burden in clinical practice：symptom-free outcome at one year [J]. Heart Lung，2015， 44（6）：487-493.
[7] 王东，肖亮亮，王晓峰.冠心舒通胶囊治疗急性心肌梗死患者的临床研究[J].新疆中医药，2016，34（2）：5-8.
[8] 李静，王建榜，王西辉.冠心舒通胶囊预防急性心肌梗死PCI术后再狭窄的临床研究[J].现代药物与临床，2015， 30（4）：404-408.
[9] 龚肖丽，吕新湖，米杰，等.替罗非班对急性心肌梗死患者PCI术后血小板活化功能、TIMI血流分级及心肌梗死面积的影响[J].河北医药，2016，38（9）：1330-1332.
[10] 王刚，李士科，张鑫杰，等.冠心舒通胶囊治疗急性心肌梗死患者的临床分析[J].中药药理与临床，2016，32（1）：195-197.
[11] 林传焕，刘毅君，谷欣.丹参酮ⅡA磺酸钠对急性冠脉综合征患者氧化应激水平的影响[J].中国循证心血管医学杂志，2017，9（1）：63-66.
[12] 崔英华，王林.丹红注射液对急诊经皮冠状动脉介入治疗后急性心肌梗死患者氧化应激和炎症反应的影响[J].中国医院药学杂志，2014，34（3）：215-218.
[13] 徐杰，刘德山.丹参川芎嗪注射液对急性心肌梗死PCI术后患者氧化应激和心功能的影响研究[J].中国生化药物杂志，2017，37（8）：129-132.
[14] 侯海文，陈礴，田承亮，等.替格瑞洛辅助PCI治疗老年ST段抬高型急性心肌梗死对氧化应激及炎症因子水平的影响分析[J].海南医学院学报，2017，23（11）：1463-1466.
[15] Sardella G，Conti G，Donahue M，et al. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis：the ROMA trial [J]. Catheter Cardiovasc Interv，2013，81（1）：36-43.
[16] 余波，艾芬，杨飞燕.瑞舒伐他汀对急性心肌梗死PCI术后患者血清cTn1、CK-MB、Myo及血小板活化功能、炎性因子水平的影响[J].海南医学院学报，2016，22（19）：2269-2272.
[17] 叶明，艾辉，曾玉杰.丹参多酚酸盐对急性心肌梗死PCI术后患者血管内皮和血小板活化功能的影响[J].安徽医药，2014，18（11）：2178-2182.
[18] 韦华清，兰枝东.急性心肌梗死并发左心室血栓患者血小板参数的相关性分析[J]. 广西医学，2013，35（9）：1216-1217.
[19] 鲁硕，王亦舒，侯凤霞.急性心肌梗死经皮冠状动脉介入治疗术后支架内血栓伴血小板减少二例[J].中国介入心脏病学杂志，2014，22（6）：403-405.
[20] 郭小燕，冯玉宝，许艳梅，等.血栓弹力图评价替格瑞洛和氯吡格雷在急性ST段抬高型心肌梗死中抗血小板的疗效[J].国际心血管病杂志，2016，43（5）：307-310.
2018, Vol. 15 
京公网安备 11010502046598号